Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael S Weiss

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Leukemia & Lymphoma|June 21, 2023
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphomaDanielle S Wallace, Chris Rowland, Brian T Hill, et al.
Journal of Occupational and Environmental Medicine|July 3, 2014
ACOEM practice guidelines: opioids and safety-sensitive workKurt T Hegmann, Michael S Weiss, Kirk Bowden, et al.
The New England Journal of Medicine|August 24, 2022
Ublituximab versus Teriflunomide in Relapsing Multiple SclerosisLawrence Steinman, Edward Fox, Hans-Peter Hartung, et al.
Journal of Occupational and Environmental Medicine|November 22, 2014
ACOEM practice guidelines: opioids for treatment of acute, subacute, chronic, and postoperative painKurt T Hegmann, Michael S Weiss, Kirk Bowden, et al.
Journal of Occupational and Environmental Medicine|November 8, 2014
Opioids and safety-sensitive workKurt T Hegmann, Michael S Weiss, Kirk Bowden, et al.
Blood Advances|October 23, 2023
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemiaBrian T Hill, Shuo Ma, Clive S Zent, et al.
Journal of Occupational and Environmental Medicine|March 26, 2021
Invasive Treatments for Low Back DisordersKurt T Hegmann, Russell Travis, Gunnar B J Andersson, et al.
The Lancet. Haematology|February 25, 2021
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trialJeff P Sharman, Danielle M Brander, Anthony R Mato, et al.
ACS Medicinal Chemistry Letters|August 25, 2017
Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer ModelsYoung K Chen, Tiziana Bonaldi, Alessandro Cuomo, et al.
Journal of Occupational and Environmental Medicine|January 25, 2020
Non-Invasive and Minimally Invasive Management of Low Back DisordersKurt T Hegmann, Russell Travis, Gunnar B J Andersson, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Leukemia & Lymphoma|June 21, 2023
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphomaDanielle S Wallace, Chris Rowland, Brian T Hill, et al.
Journal of Occupational and Environmental Medicine|July 3, 2014
ACOEM practice guidelines: opioids and safety-sensitive workKurt T Hegmann, Michael S Weiss, Kirk Bowden, et al.
The New England Journal of Medicine|August 24, 2022
Ublituximab versus Teriflunomide in Relapsing Multiple SclerosisLawrence Steinman, Edward Fox, Hans-Peter Hartung, et al.
Journal of Occupational and Environmental Medicine|November 22, 2014
ACOEM practice guidelines: opioids for treatment of acute, subacute, chronic, and postoperative painKurt T Hegmann, Michael S Weiss, Kirk Bowden, et al.
Journal of Occupational and Environmental Medicine|November 8, 2014
Opioids and safety-sensitive workKurt T Hegmann, Michael S Weiss, Kirk Bowden, et al.
Blood Advances|October 23, 2023
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemiaBrian T Hill, Shuo Ma, Clive S Zent, et al.
Journal of Occupational and Environmental Medicine|March 26, 2021
Invasive Treatments for Low Back DisordersKurt T Hegmann, Russell Travis, Gunnar B J Andersson, et al.
The Lancet. Haematology|February 25, 2021
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trialJeff P Sharman, Danielle M Brander, Anthony R Mato, et al.
ACS Medicinal Chemistry Letters|August 25, 2017
Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer ModelsYoung K Chen, Tiziana Bonaldi, Alessandro Cuomo, et al.
Journal of Occupational and Environmental Medicine|January 25, 2020
Non-Invasive and Minimally Invasive Management of Low Back DisordersKurt T Hegmann, Russell Travis, Gunnar B J Andersson, et al.
Pageof 4